Overview

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.

Phase:

PHASE3

Details

Lead Sponsor:

HighTide Biopharma Pty Ltd

Collaborator:

Shenzhen HighTide Biopharmaceutical Ltd.

Treatments:

dapagliflozin